Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TAK stock hub

Takeda Pharmaceutical Company Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TAKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

52.6B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

TAK

In the news

Latest news · TAK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E30.9

P25 12.6P50 18.3P75 33.7

Trailing P/E73

P25 15P50 23.3P75 38.5

ROE1.5

P25 -106.6P50 -46.9P75 -3.1

ROIC2.8

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TAK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

266

Groups with data

Currency

JPY

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001395064
Company name	Takeda Pharmaceutical Company Limited
Country	Japan
Country code	US
Cusip	874060205
Employees	47,455
Employees Change	-1,826%
Employees Change Percent	-3.71
Enterprise value	$83B
Exchange	NYSE
Financial currency	JPY
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US8740602052
Last refreshed	2026-05-10
Market cap	$52.6B
Market cap category	Large-Cap
Price	$16.46
Price currency	USD
Rev Per Employee	600,047.47x
Sector	Healthcare
Sic	2834
Symbol	TAK
Website	https://www.takeda.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.37%
EV Earnings	115.28x
EV Sales Forward	0.02x
EV/EBIT	21.58x
EV/EBITDA	10.22x
EV/FCF	12.87x
EV/Sales	2.92x
FCF yield	12.27%
Forward P/E	30.86x
P/B ratio	1.08x
P/E ratio	73.01x
P/S ratio	1.85x
PE Ratio10 Y	54.57x
PE Ratio3 Y	53.83x
PE Ratio5 Y	40.18x
PS Forward	0.02x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	13.51%
EBITDA Margin	28.53%
FCF margin	22.65%
Gross margin	65.52%
Gross Profit	$18.7B
Gross Profit Growth	-2.28%
Gross Profit Growth Q	8.7%
Gross Profit Growth3 Y	3.03%
Gross Profit Growth5 Y	7.41%
Net Income	$720.2M
Net Income Growth	-45.73%
Net Income Growth Q	335.66%
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Net Income Growth3 Y	-25.63%
Net Income Growth5 Y	-8.97%
Pretax Margin	4.6%
Profit Margin	2.53%
Profit Per Employee	$15,177
Profitable Years	9
ROA	2.47
Roa5y	2.47
ROCE	4.71
ROE	1.5
Roe5y	4.15
ROIC	2.76
Roic5y	4.35

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-1.22%
Cagr15y	-0.89%
Cagr1y	11.22%
Cagr3y	2.12%
Cagr5y	2.81%
Div CAGR10	5.67%
Div CAGR3	0.83%
Div CAGR5	-4.72%
EPS Growth	-45.86
EPS Growth Q	330.2
EPS Growth Quarters	1
EPS Growth Years	0
EPS Growth3 Y	-26.17
EPS Growth5 Y	-9.3
FCF Growth	10.2%
FCF Growth Q	-2.08%
FCF Growth3 Y	3.23%
FCF Growth5 Y	8.15%
OCF Growth	6.78%
OCF Growth Q	-2.74%
OCF Growth10 Y	19.3%
OCF Growth3 Y	3.94%
OCF Growth5 Y	8.37%
Revenue Growth	-2.5x
Revenue Growth Q	4.16x
Revenue Growth Quarters	1x
Revenue Growth Years	4x
Revenue Growth3 Y	4.21x
Revenue Growth5 Y	6.89x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.29
Assets	$98.3B
Cash	$4.2B
Current Assets	$19.9B
Current Liabilities	$16.7B
Debt	$34.6B
Debt EBITDA	$4.09
Debt Equity	$0.71
Debt FCF	$5.36
Equity	$48.8B
Interest Coverage	4.62
Liabilities	$49.5B
Long Term Assets	$78.4B
Long Term Liabilities	$32.9B
Net Cash	$-30.4B
Net Cash By Market Cap	$-57.82
Net Debt EBITDA	$3.74
Net Debt Equity	$0.62
Net Debt FCF	$4.71
Tangible Book Value	$-10.4B
Tangible Book Value Per Share	$-6.57
WACC	3.42

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.19
Inventory Turnover	1.16
Net Working Capital	$2.8B
Quick ratio	0.54
Working Capital	$3.2B
Working Capital Turnover	$0.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.25%
Dividend Growth	4.37%
Dividend Growth Years	1%
Dividend per share	$0.53
Dividend Years	7
Dividend Yield	3.21%
Ex Div Date	2025-09-30
Last Dividend	$0.25
Payout Ratio	117.4%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-11.56%
1Y total return	11.21%
200-day SMA	15.83
3Y total return	6.51%
50-day SMA	17.7
50-day SMA vs 200-day SMA	50over200
5Y total return	14.83%
All Time High	31.29
All Time High Change	-47.4%
All Time High Date	2018-02-01
All Time Low	12.28
All Time Low Change	34.04%
All Time Low Date	2022-10-21
ATR	0.27
Beta	0.1
Ch YTD	5.58
High	16.66
High52	18.9
High52 Date	2026-04-01
High52ch	-12.89%
Low	16.46
Low52	12.99
Low52 Date	2025-10-30
Low52ch	26.71%
Ma50ch	-6.98%
Premarket Change Percent	0.72
Premarket Price	$16.76
Premarket Volume	200
Price vs 200-day SMA	3.99%
RSI	35.15
RSI Monthly	54.69
RSI Weekly	48.1
Sharpe ratio	0.43x
Sortino ratio	0.85
Total Return	2.96%
Tr YTD	5.58
Tr15y	-12.51%
Tr1m	-10.01%
Tr1w	-0.96%
Tr3m	-7.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$0.21
Earnings EPS Estimate Growth	31.25
Earnings Revenue Estimate	7,050,000,000x
Earnings Revenue Estimate Growth	0.48x
Operating Income	$3.8B
Operating Income Growth	0.19
Operating Income Growth Q	963.6
Operating Income Growth3 Y	2.45
Operating Income Growth5 Y	20.07
Operating margin	13.51

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,578,176,279%
Float Percent	99.91%
Net Borrowing	-1,128,592,568.4
Shares Insiders	0.11%
Shares Institutions	47.16%
Shares Out	1,579,596,411
Shares Qo Q	1.77%
Shares Yo Y	0.25%
Short Float	0.3%
Short Ratio	1.53
Short Shares	0.3

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$6B
Average Volume	2,710,282.55x
Bv Per Share	30.86
CAPEX	$-1.1B
Ch10y	-31.24
Ch15y	-31.98
Ch1m	-10.01
Ch1w	-0.96
Ch1y	9.3
Ch3m	-7.99
Ch3y	-2.43
Ch5y	-2.43
Ch6m	20.5
Change	-1.08%
Change From Open	-1.2
Close	16.64
Days Gap	0.12
Depreciation Amortization	4,281,465,727.7
Dollar Volume	71,781,368.7
Earnings Date	2026-05-13
Earnings Time	bmo
EBIT	$3.8B
EBITDA	$8.1B
EPS	$0.45
F Score	6
FCF	$6.5B
FCF EV Yield	7.77x
FCF Per Share	$4.08
Financing CF	-4,599,331,484
Fiscal Year End	March
Founded	1,781
Goodwill	36,723,368,503.9
Graham Number	8.79852
Graham Upside	-46.55
Income Tax	$588M
Investing CF	-2,109,887,191
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-01-29
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2025-06-25
Lynch Fair Value	$1.13
Lynch Upside	-93.15
Ma150	16.16
Ma150ch	1.83%
Ma20	16.95
Ma20ch	-2.87%
Net CF	1,025,652,452
Next Earnings Date	2026-05-22
Open	16.66
Optionable	Yes
P FCF Ratio	8.15
P OCF Ratio	6.93
Payment Date	2025-12-11
Position In Range	0
Post Close	16.46
Postmarket Change Percent	0.06
Postmarket Price	$16.47
Ppne	13,302,144,488.7
Pre Close	16.64
Price Date	2026-05-08
Price EBITDA	$6.47
Relative Volume	1.61x
Revenue	28,475,252,603x
SBC By Revenue	1.58x
Share Based Comp	450,869,955
Tax By Revenue	2.06x
Tax Rate	44.89%
Tr6m	20.5%
Volume	4,360,958
Z Score	1.08

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TAK dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.2%

$0.53 annual per share

Payout ratio

+117.4%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-4.7%

1 consecutive years of growth

Total shareholder yield

+3.0%

Next ex-dividend date: 2025-09-30

Performance

TAK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TAK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+47.2%

Float: +99.9% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TAK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

35.2

Neutral momentum band

Price vs 200-day MA

+4.0%

50/200-day relationship not available

Beta (5Y)

0.10

Less volatile than the market

Sharpe ratio

0.43

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TAK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TAK stock rating?

Takeda Pharmaceutical Company Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TAK analysis?

The full report lives at /stocks/TAK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TAK?

The latest report frames TAK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TAK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.